NCCS Cancer Policy Roundtable

In 2019, NCCS launched its 19th year of semi-annual Cancer Policy Roundtable (CPR) “think tank” meetings, convening stakeholders in the cancer community to discuss pressing issues related to cancer research, development of new cancer therapies, and the delivery of quality cancer care.

Participants include advocates, providers, payers, researchers, government officials, and pharmaceutical and biotechnology company representatives.

The CPR Fall 2019 meeting will be held at the Four Seasons Hotel in Washington, DC, on November 14, 2019. A summary of the CPR Spring 2019 meeting can be found here [PDF].

The faculty that present at the Cancer Policy Roundtable range from public and health policy experts to representatives from the National Institutes of Health, Food and Drug Administration, Centers for Medicare and Medicaid Services, Congressional Health Policy Advisors and leaders in health insurance, pharmaceutical, and biotechnology industries.

These meetings are a great opportunity for interested parties to come together and discuss timely and compelling issues.  Specific objectives and outcomes are unique to each meeting, however past meetings have focused on topics such as clinical trials, issues for older adults, expanded access programs, Medicare reimbursement, health care reform and other relevant topics.

For information on how to become a participant of this event, please contact us.

Cancer Policy Roundtable Spring 2019 Summary

Read below a summary of the panel discussions and presentations from the CPR Spring 2019 meeting. The keynote speakers for the meeting were outgoing FDA Commissioner Dr. Scott Gottlieb and outgoing NCI Director Dr. Ned Sharpless.

Read or download the summary in a separate window » [PDF]

Otis Brawley, MD at CPR Spring 2018

CPR Spring 2018 Meeting: Otis Brawley, MD, then-CMO of the American Cancer Society, participates in a panel discussion about Overtreament and Overdiagnosis.

Cancer Policy Roundtable Sponsors

BIO (Biotechnology Industry Organization)
Bristol-Myers Squibb
Jazz Pharmaceuticals

Kite Pharma, a Gilead Company
Merck & Co.
Verastem Oncology

(as of 11/10/2019)